Cambridge Investment Research Advisors
CAI

Cambridge Investment Research Advisors’s Caris Life Sciences CAI Stock Holding History

Cambridge Investment Research Advisors’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
+59,873
New +$1.07M ﹤0.01% 2090

Other funds holding CAI

ZCI
Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return
SIC
Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return

Cambridge Investment Research Advisors's CAI Position: Q2 2026 in Review

Cambridge Investment Research Advisors opened a new position in Caris Life Sciences (CAI) in Q2 2026: 59,873 shares worth $1.07M. The stake represents ﹤0.01% of the portfolio and ranks #2090 among its holdings.

36 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Cambridge Investment Research Advisors held 59,873 shares of Caris Life Sciences worth $1.07M as of Q2 2026.
  • Caris Life Sciences was a new Cambridge Investment Research Advisors position in Q2 2026.
  • Caris Life Sciences made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #2090 holding.
  • 36 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.